MediWound Ltd. - Ordinary Shares (MDWD): Price and Financial Metrics
MDWD Price/Volume Stats
| Current price | $16.84 | 52-week high | $18.75 |
| Prev. close | $16.41 | 52-week low | $7.10 |
| Day low | $16.26 | Volume | 13,257 |
| Day high | $16.99 | Avg. volume | 67,934 |
| 50-day MA | $15.20 | Dividend yield | N/A |
| 200-day MA | $11.06 | Market Cap | 159.85M |
MDWD Stock Price Chart Interactive Chart >
MediWound Ltd. - Ordinary Shares (MDWD) Company Bio
MediWound Ltd. focuses on developing, manufacturing, and commercializing products for the treatment of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and others. The company was founded in 2000 and is based in Yavne, Israel.
Latest MDWD News From Around the Web
Below are the latest news stories about MEDIWOUND LTD that investors may wish to consider to help them evaluate MDWD as an investment opportunity.
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. ArmyAwarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 millionYAVNE, Israel, Dec. 28, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Department of Defense (DoD), through the Medical Technology Enterprise Consortium (MTEC), has awarded MediWound an additional $6.7 million i |
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial LoadsResults show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridementYAVNE, Israel, Dec. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair today announced the publication of a peer-reviewed paper, titled “An Open-label, Proof of Concept Study, Assessing the Effects of Bromelain-Based Enzymatic Debridement on Biofilm and Microbial Loads in Patients with |
MediWound Ltd. (NASDAQ:MDWD) Stock Rockets 26% As Investors Are Less Pessimistic Than ExpectedMediWound Ltd. ( NASDAQ:MDWD ) shareholders would be excited to see that the share price has had a great month, posting... |
Wall Street Analysts Believe MediWound (MDWD) Could Rally 171.79%: Here's is How to TradeThe average of price targets set by Wall Street analysts indicates a potential upside of 171.8% in MediWound (MDWD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
MediWound (NASDAQ:MDWD) investors are sitting on a loss of 75% if they invested five years agoWhile not a mind-blowing move, it is good to see that the MediWound Ltd. ( NASDAQ:MDWD ) share price has gained 14% in... |
MDWD Price Returns
| 1-mo | 6.38% |
| 3-mo | 30.75% |
| 6-mo | 116.73% |
| 1-year | 42.11% |
| 3-year | -48.04% |
| 5-year | -55.70% |
| YTD | 65.59% |
| 2023 | -24.61% |
| 2022 | -18.34% |
| 2021 | -36.22% |
| 2020 | 19.35% |
| 2019 | -23.65% |
Continue Researching MDWD
Want to do more research on MediWound Ltd's stock and its price? Try the links below:MediWound Ltd (MDWD) Stock Price | Nasdaq
MediWound Ltd (MDWD) Stock Quote, History and News - Yahoo Finance
MediWound Ltd (MDWD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...